HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer. (October 2020)

Record Type:: Journal Article
Title:: HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer. (October 2020)
Main Title:: HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer
Authors:: Xu, B.
Zhang, Q.
Sun, T.
Li, W.
Teng, Y.
Hu, X.
Bondarenko, I.
Adamchuk, H.
Li, Y.
Shan, B.
Cheng, J.
Wang, X.
Chen, Y.
Jiang, W.
Liu, S.
Zhang, X.
Liu, E.
Luk, A.
Wang, Q.
Chai, K.
Abstract:
Is Part Of:: European journal of cancer. Volume 138(2020)Supplement 1
Journal:: European journal of cancer
Issue:: Volume 138(2020)Supplement 1
Issue Display:: Volume 138, Issue 1 (2020)
Year:: 2020
Volume:: 138
Issue:: 1
Issue Sort Value:: 2020-0138-0001-0000
Page Start:: S68
Page End:
Publication Date:: 2020-10
Subjects:: Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:: http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0959-8049(20)30708-5 ↗
Languages:: English
ISSNs:: 0959-8049
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 21844.xml